A patient with urinary tract tuberculosis during treatment with etanercept

about

Rituximab Can Induce Remission in a Patient with Ankylosing Spondylitis Who Failed Anti-TNF-α Agent.

P2860

Q41895311-BE205FFF-337E-4937-8BC4-84277E007600

P2860

A patient with urinary tract tuberculosis during treatment with etanercept

Item

http://www.wikidata.org/entity/Q35743054

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A patient with urinary tract tuberculosis during treatment with etanercept

@ast

A patient with urinary tract tuberculosis during treatment with etanercept

@en

type

Item

label

A patient with urinary tract tuberculosis during treatment with etanercept

@ast

A patient with urinary tract tuberculosis during treatment with etanercept

@en

prefLabel

A patient with urinary tract tuberculosis during treatment with etanercept

@ast

A patient with urinary tract tuberculosis during treatment with etanercept

@en

P1476

A patient with urinary tract tuberculosis during treatment with etanercept

@en

P2093

Eisuke Shono

http://www.w3.org/2001/XMLSchema#string

Emi Nishimagi

http://www.w3.org/2001/XMLSchema#string

Ken Yamaura

http://www.w3.org/2001/XMLSchema#string

Shiho Shibata

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Clinical practice. Latent tuberculosis infection

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Genitourinary manifestations of tuberculosis.

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.

An update on the diagnosis of tuberculosis infection.

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

P304

341-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12659/AJCR.893416

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26040918

http://www.w3.org/2001/XMLSchema#string

P932

4467601

http://www.w3.org/2001/XMLSchema#string

A patient with urinary tract tuberculosis during treatment with etanercept

about

P2860

P2860

A patient with urinary tract tuberculosis during treatment with etanercept

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932